Bio-Techne Corp. Stock
Bio-Techne Corp. Stock
We can see a decrease in the price for Bio-Techne Corp.. Compared to yesterday it has lost -€1.000 (-1.900%).
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Bio-Techne Corp..
With a target price of 60 € there is a slightly positive potential of 16.5% for Bio-Techne Corp. compared to the current price of 51.5 €.
So far the community has only identified positive things for Bio-Techne Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Bio-Techne Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Techne Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Techne Corp. | -1.900% | -2.830% | -2.830% | -29.932% | -25.899% | -34.810% | - |
| Icu Medical Inc. | 0.000% | 3.306% | 1.626% | -20.886% | -14.966% | -14.966% | -22.360% |
| Bio-Rad Labs Inc. A | 1.740% | -1.966% | -4.673% | -17.189% | -14.263% | -31.823% | -41.201% |
| Neogen Corp. | -2.480% | 13.592% | 4.464% | -51.250% | -51.250% | - | - |
Comments
Bio-Techne (NASDAQ:TECH) was given a new $72.00 price target on by analysts at Deutsche Bank Aktiengesellschaft. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Argus from $65.00 to $68.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at UBS Group AG from $65.00 to $70.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat